Bellevue Group AG
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Bellevue Group AG reported 162 stock positions worth $6.2 billion. Its top holding was Argenx SE - ADR (ARGX) at 5.6% of the portfolio, followed by Ionis Pharmaceuticals (IONS, 5.1%) and Vertex Pharmaceuticals (VRTX, 4.3%). Compared with Q2 2024, it opened 11 new positions, sold out of 15, added to 57 and reduced 71. The biggest buy was Exact Sciences (EXAS, shares +25%) and the biggest sale Ionis Pharmaceuticals (IONS, shares −5%).
- Most Recent 13F
- Q2 2026
- Location
- ZURICH, V8
- CIK
- 0001674546
- Portfolio Value
- $6.2B (Q3 2024)
- SEC Filing
- 0000950123-24-011906 ↗ filed Nov 14, 2024
Holdings Value
Holdings 162 stocks · $6.2B
| ARGX Argenx SE - ADR | 5.56% | 632,829 | $343.0M | Reduce -8.5% |
| IONS Ionis Pharmaceuticals Inc. | 5.11% | 7,874,400 | $315.4M | Reduce -4.7% |
| VRTX Vertex Pharmaceuticals Inc. | 4.31% | 571,406 | $265.7M | Reduce -3.7% |
| ISRG Intuitive Surgical Inc. | 3.95% | 496,775 | $244.1M | Reduce -8.0% |
| ALNY Alnylam Pharmaceuticals Inc. | 3.61% | 809,095 | $222.5M | Reduce -12.0% |
| RVMD Revolution Medicines Inc. | 3.58% | 4,871,360 | $220.9M | Reduce -3.1% |
| NBIX Neurocrine Biosciences Inc. | 3.48% | 1,863,800 | $214.7M | Reduce -1.8% |
| BSX Boston Scientific Corp. | 3.33% | 2,452,797 | $205.5M | Reduce -4.5% |
| ABT Abbott Laboratories | 3.22% | 1,743,938 | $198.8M | Add +8.6% |
| SYK Stryker Corp. | 3.08% | 526,607 | $190.2M | Reduce -3.5% |
| ITCI Intra-Cellular Therapies Inc. | 2.95% | 2,485,627 | $181.9M | Add +0.6% |
| AGIO Agios Pharmaceuticals Inc. | 2.69% | 3,735,915 | $166.0M | Reduce -3.7% |
| INCY Incyte Corp. | 2.30% | 2,150,551 | $142.2M | Reduce -0.1% |
| UNH Unitedhealth Group Inc. | 2.14% | 225,550 | $131.9M | Add +9.7% |
| MRNA Moderna Inc. | 1.73% | 1,600,836 | $107.0M | Add +2.4% |
| CLDX Celldex Therapeutics Inc. | 1.69% | 3,071,615 | $104.4M | Add +3.4% |
| BHVN Biohaven Ltd. | 1.65% | 2,040,853 | $102.0M | No change |
| EXAS Exact Sciences Corp. | 1.60% | 1,449,465 | $98.7M | Add +25.1% |
| CDNA Caredx Inc. | 1.59% | 3,145,456 | $98.2M | Reduce -19.6% |
| PODD Insulet Corp. | 1.59% | 421,479 | $98.1M | Reduce -3.2% |
| MDT Medtronic PLC | 1.47% | 1,008,633 | $90.8M | Add +0.7% |
| BDX Becton Dickinson and Co. | 1.32% | 337,633 | $81.4M | Reduce -2.8% |
| TNDM Tandem Diabetes Care Inc. | 1.27% | 1,850,891 | $78.5M | Add +19.9% |
| EVH Evolent Health Inc. Class A | 1.22% | 2,670,050 | $75.5M | Add +59.9% |
| EW Edwards Lifesciences Corp. | 1.21% | 1,134,076 | $74.8M | Reduce -10.0% |
| DXCM Dexcom Inc. | 1.10% | 1,017,038 | $68.2M | Reduce -19.8% |
| ARVN Arvinas Inc. | 0.95% | 2,386,600 | $58.8M | Reduce -0.2% |
| PEN Penumbra Inc. | 0.86% | 272,683 | $53.0M | Reduce -3.3% |
| RLAY Relay Therapeutics Inc. | 0.85% | 7,377,184 | $52.2M | Add +15.7% |
| OPCH Option Care Health Inc. | 0.84% | 1,654,878 | $51.8M | Add +16.8% |
| GEHC GE Healthcare Technology | 0.81% | 531,967 | $49.9M | Add +2.1% |
| PRCT Procept Biorobotics Corp. | 0.80% | 612,691 | $49.1M | Reduce -8.4% |
| EPIX Essa Pharma Inc. | 0.77% | 7,879,583 | $47.8M | Reduce -0.1% |
| ZBH Zimmer Biomet Holdings Inc. | 0.76% | 432,805 | $46.7M | Reduce -3.6% |
| HCA HCA Healthcare Inc. | 0.75% | 114,525 | $46.5M | Reduce -6.4% |
| ELV Elevance Health Inc. | 0.75% | 89,328 | $46.5M | Reduce -12.0% |
| IDXX Idexx Laboratories Inc. | 0.75% | 91,279 | $46.1M | Reduce -2.2% |
| COO The Cooper Cos Inc. | 0.71% | 397,373 | $43.8M | No change |
| SRPT Sarepta Therapeutics Inc. | 0.70% | 344,348 | $43.0M | Add +36.5% |
| EXEL Exelixis Inc. | 0.67% | 1,600,000 | $41.5M | Reduce -11.3% |
| INSP Inspire Medical Systems Inc. | 0.67% | 195,080 | $41.2M | Add +56.4% |
| CI The Cigna Group | 0.66% | 118,407 | $41.0M | Reduce -3.8% |
| LLY Eli Lilly & Co. | 0.64% | 44,246 | $39.2M | Reduce -10.9% |
| RMD Resmed Inc. | 0.63% | 160,128 | $39.1M | Add +2.7% |
| INSM Insmed Inc. | 0.62% | 525,434 | $38.4M | Reduce -48.6% |
| EWTX Edgewise Therapeutics Inc. | 0.62% | 1,428,929 | $38.1M | No change |
| IMCR Immunocore Holdings PLC-ADR | 0.61% | 1,205,464 | $37.5M | Add +4.4% |
| BEAM Beam Therapeutics Inc. | 0.60% | 1,518,121 | $37.2M | Add +7.0% |
| BDTX Black Diamond Therapeutics I | 0.60% | 8,517,839 | $37.1M | No change |
| ALGN Align Technology Inc. | 0.59% | 143,996 | $36.6M | Add +0.0% |
| CSTL Castle Biosciences Inc. | 0.58% | 1,262,030 | $36.0M | Add +3.7% |
| VRNA Verona Pharma Ltd. | 0.57% | 1,220,059 | $35.1M | Add +7.6% |
| VEEV Veeva Systems Inc. Class A | 0.56% | 163,512 | $34.3M | Reduce -3.0% |
| GMED Globus Medical Inc. Class A | 0.54% | 469,798 | $33.6M | Reduce -5.5% |
| WVE Wave Life Sciences Ltd. | 0.54% | 4,094,458 | $33.6M | No change |
| TMO Thermo Fisher Scientific Inc. | 0.54% | 53,623 | $33.2M | Add +25.8% |
| AXSM Axsome Therapeutics Inc. | 0.53% | 367,181 | $33.0M | Reduce -28.9% |
| MGNX Macrogenics Inc. | 0.53% | 9,929,963 | $32.7M | Reduce -0.1% |
| SAGE Sage Therapeutics Inc. | 0.52% | 4,460,693 | $32.2M | Reduce -0.1% |
| IQV Iqvia Holdings Inc. | 0.50% | 129,827 | $30.8M | Add +41.0% |
| ANNX Annexon Inc. | 0.49% | 5,157,290 | $30.5M | No change |
| DHR Danaher Corp. | 0.48% | 105,590 | $29.4M | Add +25.8% |
| CRSP Crispr Therapeutics AG | 0.46% | 610,000 | $28.7M | Reduce -1.2% |
| REGN Regeneron Pharmaceuticals | 0.46% | 26,776 | $28.1M | Reduce -17.1% |
| GPCR Structure Therapeutics Inc. | 0.45% | 629,758 | $27.6M | Add +13.0% |
| TMDX Transmedics Group Inc. | 0.43% | 169,844 | $26.7M | Reduce -15.7% |
| NEO Neogenomics Inc. | 0.39% | 1,612,612 | $23.8M | Add +34.1% |
| MOH Molina Healthcare Inc. | 0.38% | 67,562 | $23.3M | Reduce -11.6% |
| BMRN Biomarin Pharmaceutical Inc. | 0.38% | 330,976 | $23.3M | Add +533.7% |
| STE Steris PLC | 0.36% | 91,282 | $22.1M | No change |
| HOLX Hologic Inc. | 0.33% | 247,864 | $20.2M | Add +0.0% |
| SIBN Si-Bone Inc. | 0.33% | 1,444,109 | $20.2M | Add +4.1% |
| PRVA Privia Health Group Inc. | 0.31% | 1,059,171 | $19.3M | No change |
| MCK McKesson Corp. | 0.29% | 35,742 | $17.7M | Reduce -22.5% |
| NTRA Natera Inc. | 0.28% | 138,459 | $17.6M | Reduce -35.3% |
| SRRK Scholar Rock Holding Corp. | 0.28% | 2,161,203 | $17.3M | Reduce -0.2% |
| FATE Fate Therapeutics Inc. | 0.27% | 4,839,779 | $16.9M | No change |
| ESPR Esperion Therapeutics Inc. | 0.27% | 9,944,064 | $16.4M | No change |
| COR Cencora Inc. | 0.26% | 72,053 | $16.2M | Reduce -19.3% |
| BIO Bio-Rad Laboratories-A | 0.25% | 46,151 | $15.4M | Reduce -70.3% |
| ASTH Astrana Health Inc. | 0.24% | 254,182 | $14.7M | Add +1.4% |
| CRL Charles River Laboratories | 0.23% | 73,115 | $14.4M | Reduce -68.6% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 0.21% | 58,729 | $13.2M | Add +129.2% |
| GBIO Generation Bio Co. | 0.16% | 3,918,856 | $9.7M | No change |
| PHR Phreesia Inc. | 0.16% | 422,406 | $9.6M | Reduce -4.7% |
| HUM Humana Inc. | 0.15% | 28,440 | $9.0M | No change |
| TERN Terns Pharmaceuticals Inc. | 0.14% | 1,042,135 | $8.7M | New |
| OMCL Omnicell Inc. | 0.14% | 197,714 | $8.6M | Reduce -16.0% |
| ABBV Abbvie Inc. | 0.14% | 42,886 | $8.5M | Add +1.6% |
| JNJ Johnson & Johnson | 0.13% | 51,242 | $8.3M | Add +557.2% |
| LEGN Legend Biotech Corp.-ADR | 0.13% | 169,134 | $8.2M | Reduce -54.2% |
| GKOS Glaukos Corp. | 0.13% | 62,983 | $8.2M | Add +12.6% |
| AMGN Amgen Inc. | 0.13% | 25,152 | $8.1M | Reduce -14.8% |
| CNC Centene Corp. | 0.11% | 86,708 | $6.5M | Reduce -79.4% |
| TXG 10X Genomics Inc. Class A | 0.10% | 281,881 | $6.4M | Reduce -8.6% |
| ILMN Illumina Inc. | 0.10% | 45,196 | $5.9M | Add +3.7% |
| ALT Altimmune Inc. | 0.09% | 863,660 | $5.3M | Add +43.9% |
| MRK Merck & Co. Inc. | 0.08% | 42,233 | $4.8M | Reduce -43.5% |
| WAY Waystar Holding Corp. | 0.07% | 150,202 | $4.2M | Add +0.1% |
| PFE Pfizer Inc. | 0.07% | 141,075 | $4.1M | Add +59.2% |
Options reported separately and not counted above: SUMMIT THERAPEUTICS INC calls ($219K).
Portfolio Sells Q2 2024 → Q3 2024
| IONS Ionis Pharmaceuticals Inc. | Reduce -4.7% | 5.11% | −1.29 |
| DXCM Dexcom Inc. | Reduce -19.8% | 1.10% | −1.23 |
| NBIX Neurocrine Biosciences Inc. | Reduce -1.8% | 3.48% | −0.77 |
| EW Edwards Lifesciences Corp. | Reduce -10.0% | 1.21% | −0.68 |
| CRL Charles River Laboratories | Reduce -68.6% | 0.23% | −0.55 |
| INSM Insmed Inc. | Reduce -48.6% | 0.62% | −0.49 |
| BIO Bio-Rad Laboratories-A | Reduce -70.3% | 0.25% | −0.44 |
| SILK Silk Road Medical Inc. | Sold out | 0.00% | −0.38 |
| CNC Centene Corp. | Reduce -79.4% | 0.11% | −0.35 |
| HCM Hutchmed China-ADR | Reduce -97.9% | 0.01% | −0.31 |
| APLS Apellis Pharmaceuticals Inc. | Reduce -95.7% | 0.01% | −0.27 |
| SAGE Sage Therapeutics Inc. | Reduce -0.1% | 0.52% | −0.27 |
| VRTX Vertex Pharmaceuticals Inc. | Reduce -3.7% | 4.31% | −0.21 |
| MGNX Macrogenics Inc. | Reduce -0.1% | 0.53% | −0.16 |
| MCK McKesson Corp. | Reduce -22.5% | 0.29% | −0.15 |
| ELV Elevance Health Inc. | Reduce -12.0% | 0.75% | −0.14 |
| AXSM Axsome Therapeutics Inc. | Reduce -28.9% | 0.53% | −0.14 |
| LEGN Legend Biotech Corp.-ADR | Reduce -54.2% | 0.13% | −0.13 |
| LLY Eli Lilly & Co. | Reduce -10.9% | 0.64% | −0.10 |
| REGN Regeneron Pharmaceuticals | Reduce -17.1% | 0.46% | −0.10 |
| NTRA Natera Inc. | Reduce -35.3% | 0.28% | −0.09 |
| ARVN Arvinas Inc. | Reduce -0.2% | 0.95% | −0.08 |
| ATRC Atricure Inc. | Sold out | 0.00% | −0.08 |
| CRSP Crispr Therapeutics AG | Reduce -1.2% | 0.46% | −0.08 |
| MRK Merck & Co. Inc. | Reduce -43.5% | 0.08% | −0.07 |
| COR Cencora Inc. | Reduce -19.3% | 0.26% | −0.06 |
| TMDX Transmedics Group Inc. | Reduce -15.7% | 0.43% | −0.06 |
| OM Outset Medical Inc. | Sold out | 0.00% | −0.05 |
| TDOC Teladoc Health Inc. | Sold out | 0.00% | −0.04 |
| ZBH Zimmer Biomet Holdings Inc. | Reduce -3.6% | 0.76% | −0.04 |
| AGIO Agios Pharmaceuticals Inc. | Reduce -3.7% | 2.69% | −0.03 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -12.0% | 3.61% | −0.03 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -54.2% | 0.02% | −0.02 |
| AMGN Amgen Inc. | Reduce -14.8% | 0.13% | −0.02 |
| NVRO Nevro LLC | Sold out | 0.00% | −0.02 |
| BIIB Biogen Inc. | Reduce -55.4% | 0.01% | −0.01 |
| SRRK Scholar Rock Holding Corp. | Reduce -0.2% | 0.28% | −0.01 |
| DOCS Doximity Inc. Class A | Reduce -59.7% | 0.02% | −0.01 |
| AZN Astrazeneca PLC-Spons ADR | Reduce -20.6% | 0.04% | −0.01 |
| RXRX Recursion Pharmaceuticals-A | Reduce -7.7% | 0.04% | −0.01 |
| ACCD Accolade Inc. | Reduce -23.9% | 0.04% | −0.01 |
| GMED Globus Medical Inc. Class A | Reduce -5.5% | 0.54% | −0.01 |
| AAPL Apple Inc. | Sold out | 0.00% | −0.01 |
| ALKS Alkermes PLC | Sold out | 0.00% | −0.01 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −0.01 |
| BCYC Bicycle Therapeutics PLC-ADR | Sold out | 0.00% | −0.01 |
| CYTK Cytokinetics Inc. | Reduce -34.3% | 0.01% | −0.01 |
| DVAX Dynavax Technologies Corp. | Sold out | 0.00% | −0.01 |
| CCCC C4 Therapeutics Inc. | Sold out | 0.00% | −0.00 |
| BPMC Blueprint Medicines Corp. | Reduce -37.3% | 0.00% | −0.00 |
Portfolio Buys Q2 2024 → Q3 2024
| EXAS Exact Sciences Corp. | Add +25.1% | 1.60% | +0.80 |
| EVH Evolent Health Inc. Class A | Add +59.9% | 1.22% | +0.70 |
| ABT Abbott Laboratories | Add +8.6% | 3.22% | +0.51 |
| UNH Unitedhealth Group Inc. | Add +9.7% | 2.14% | +0.43 |
| INSP Inspire Medical Systems Inc. | Add +56.4% | 0.67% | +0.40 |
| BMRN Biomarin Pharmaceutical Inc. | Add +533.7% | 0.38% | +0.31 |
| VRNA Verona Pharma Ltd. | Add +7.6% | 0.57% | +0.30 |
| TNDM Tandem Diabetes Care Inc. | Add +19.9% | 1.27% | +0.26 |
| OPCH Option Care Health Inc. | Add +16.8% | 0.84% | +0.20 |
| ITCI Intra-Cellular Therapies Inc. | Add +0.6% | 2.95% | +0.20 |
| MDT Medtronic PLC | Add +0.7% | 1.47% | +0.19 |
| IQV Iqvia Holdings Inc. | Add +41.0% | 0.50% | +0.18 |
| RLAY Relay Therapeutics Inc. | Add +15.7% | 0.85% | +0.17 |
| TMO Thermo Fisher Scientific Inc. | Add +25.8% | 0.54% | +0.15 |
| ONC Beone Medicines Ltd.-ADR | Add +129.2% | 0.21% | +0.15 |
| CSTL Castle Biosciences Inc. | Add +3.7% | 0.58% | +0.15 |
| GEHC GE Healthcare Technology | Add +2.1% | 0.81% | +0.15 |
| RMD Resmed Inc. | Add +2.7% | 0.63% | +0.15 |
| TERN Terns Pharmaceuticals Inc. | New | 0.14% | +0.14 |
| DHR Danaher Corp. | Add +25.8% | 0.48% | +0.13 |
| JNJ Johnson & Johnson | Add +557.2% | 0.13% | +0.12 |
| NEO Neogenomics Inc. | Add +34.1% | 0.39% | +0.11 |
| GPCR Structure Therapeutics Inc. | Add +13.0% | 0.45% | +0.09 |
| ASTH Astrana Health Inc. | Add +1.4% | 0.24% | +0.07 |
| BEAM Beam Therapeutics Inc. | Add +7.0% | 0.60% | +0.06 |
| SRPT Sarepta Therapeutics Inc. | Add +36.5% | 0.70% | +0.05 |
| SIBN Si-Bone Inc. | Add +4.1% | 0.33% | +0.04 |
| BMY Bristol-Myers Squibb Co. | New | 0.03% | +0.03 |
| ALGN Align Technology Inc. | Add +0.0% | 0.59% | +0.03 |
| HOLX Hologic Inc. | Add +0.0% | 0.33% | +0.03 |
| PFE Pfizer Inc. | Add +59.2% | 0.07% | +0.03 |
| GKOS Glaukos Corp. | Add +12.6% | 0.13% | +0.03 |
| SMMT Summit Therapeutics Inc. | New | 0.02% | +0.02 |
| ILMN Illumina Inc. | Add +3.7% | 0.10% | +0.02 |
| ALT Altimmune Inc. | Add +43.9% | 0.09% | +0.02 |
| ABBV Abbvie Inc. | Add +1.6% | 0.14% | +0.02 |
| GILD Gilead Sciences Inc. | Add +18.2% | 0.06% | +0.02 |
| BNTX Biontech SE-ADR | New | 0.02% | +0.02 |
| WAY Waystar Holding Corp. | Add +0.1% | 0.07% | +0.02 |
| SNY Sanofi-ADR | New | 0.01% | +0.01 |
| VKTX Viking Therapeutics Inc. | Add +267.7% | 0.02% | +0.01 |
| EHC Encompass Health Corp. | Add +38.7% | 0.03% | +0.01 |
| ZTS Zoetis Inc. | Add +79.7% | 0.02% | +0.01 |
| DNLI Denali Therapeutics Inc. | New | 0.01% | +0.01 |
| TVTX Travere Therapeutics Inc. | New | 0.01% | +0.01 |
| ACLX Arcellx Inc. | New | 0.01% | +0.01 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +20.8% | 0.01% | +0.00 |
| AMRX Amneal Pharmaceuticals Inc. | Add +21.8% | 0.01% | +0.00 |
| THC Tenet Healthcare Corp. | Add +3.9% | 0.02% | +0.00 |
| ARQT Arcutis Biotherapeutics Inc. | Add +125.7% | 0.01% | +0.00 |
Options Activity Q2 2024 → Q3 2024
| SUMMIT THERAPEUTICS INC | call | New | 10,000 | $219K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 148 | $4.8B | AMGN, VRTX, ARGX, GILD, RVMD |
| Q1 2026 | 155 | $4.2B | VRTX, ARGX, REGN, SRRK, GILD |
| Q4 2025 | 176 | $5.3B | RVMD, ARGX, IONS, VRTX, NBIX |
| Q3 2025 | 148 | $4.8B | IONS, ARGX, RVMD, NBIX, ALNY |
| Q2 2025 | 142 | $4.5B | ARGX, IONS, NBIX, ALNY, ABT |
| Q1 2025 | 148 | $4.5B | ARGX, IONS, SYK, ISRG, ALNY |
| Q4 2024 | 160 | $5.2B | ARGX, IONS, NBIX, ISRG, ITCI |
| Q3 2024 | 162 | $6.2B | ARGX, IONS, VRTX, ISRG, ALNY |
| Q2 2024 | 166 | $6.2B | IONS, ARGX, VRTX, NBIX, ISRG |
| Q1 2024 | 169 | $6.6B | IONS, ARGX, NBIX, VRTX, ISRG |